New pill could clear psoriasis skin in weeks
NCT ID NCT07150988
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tests an oral drug called HSK44459 for adults with moderate to severe plaque psoriasis. About 150 participants will receive either the drug or a placebo for 16 weeks. The main goal is to see if the drug can reduce psoriasis skin symptoms by at least 75%.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HSK44459 (oral drug)
What this could lead to
If successful, this could lead to a new oral treatment option for people with moderate to severe plaque psoriasis, helping clear skin symptoms.
What could go wrong
This is an early phase 2 trial with only 150 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••